Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telangiectatic osteosarcoma.

T R Mervak1, K K Unni, D J Pritchard

  • 1Mayo Clinic, Rochester, Minnesota 55905.

Clinical Orthopaedics and Related Research
|September 1, 1991
PubMed
Summary

Prognosis for telangiectatic osteosarcoma has improved significantly, now matching conventional osteosarcoma outcomes. Adjuvant chemotherapy aids metastatic cases, but its impact on non-metastatic survival remains unclear in this study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EXPERIMENTAL MANIPULATION OF ALTERNATIVE PATHWAYS OF DIFFERENTIATION IN CULTURES OF EMBRYONIC CHICK NEURAL RETINA.

Development, growth & differentiation·2023
Same author

Treating hummingbirds as feathered bees: a case of ethological cross-pollination.

Biology letters·2017
Same author

Quality evaluation of ultra-thin samples: Application to graphene.

Microscopy research and technique·2017
Same author

Validity of the dipole approximation in TEM-EELS studies.

Microscopy research and technique·2014
Same author

Chondroblastoma.

Orthopedics·2014
Same author

Mayo clinic tumor rounds.

Orthopedics·2014

Area of Science:

  • Orthopedic Oncology
  • Skeletal Tumors
  • Bone Cancer Research

Background:

  • Telangiectatic osteosarcoma (OS) is a rare osteosarcoma subtype.
  • Previous reports indicated a poor prognosis for telangiectatic OS.
  • Recent advancements necessitate an updated review of its clinical outcomes.

Purpose of the Study:

  • To re-evaluate the prognosis of telangiectatic osteosarcoma.
  • To compare current outcomes with historical data and conventional OS.
  • To assess the impact of adjuvant chemotherapy on patient survival.

Main Methods:

  • Retrospective analysis of patients diagnosed with telangiectatic osteosarcoma.
  • Comparison of survival rates based on treatment protocols (chemotherapy vs. no chemotherapy).

Related Experiment Videos

  • Evaluation of prognostic factors, including metastatic status.

    • Main Results:

    • The prognosis for telangiectatic osteosarcoma has markedly improved.
    • Current survival rates appear comparable to conventional osteosarcoma.
    • Adjuvant chemotherapy demonstrated a positive effect on salvaging patients with metastatic disease.
    • In this series, chemotherapy did not significantly influence survival in patients without metastasis.

    Conclusions:

    • Telangiectatic osteosarcoma no longer carries an inherently poor prognosis.
    • Treatment strategies, including adjuvant chemotherapy, are crucial for managing metastatic disease.
    • Further research is needed to clarify the role of chemotherapy in non-metastatic telangiectatic OS.